Abstract
Data from the North Carolina‐Louisiana Prostate Cancer Project, a population‐based study of incident prostate cancer in African Americans (n=698) and Caucasian Americans (n=904) was used to determine the association between proanthocyanidin (PA) intake and prostate tumor stage at diagnosis. PA intake was calculated from modified NCI DHQ food and nutrient database. Associations between dietary PA and tumor stage were determined by logistic regression analyses. After adjusted for other risk confounders, the odds ratio for advanced tumor stages (T3, T4) was 0.06 (95% CI: 0.01–0.50) for men in the highest quartile of PA intake. Among the sociodemographic characteristics, PSA screening was a strong predictor of advanced tumor stages (p<0.01). PA intake was inversely associated with advanced tumor stages (p<0.01). Mediation analysis revealed that the relationship between PSA screening and tumor stage was attenuated after adding PA intake into the model by changing 19% of beta coefficient. These findings demonstrate that PA intake is a mediator of PSA screening in association with advanced prostate tumor stages.Grant Funding Source: NIH Cancer Epidemiology Small Grant #1R03CA159421–01A1
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call